Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | AOC2 | O75106 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5739424 | 0.84 | ALDH1A1 (0.55) | ALDH1A1CACNA1HKDM4EUSP2GAA | |
| SCHEMBL5320828 | 0.82 | GAA (0.62) | ALDH1A1KDM4EUSP2GAA | |
| SCHEMBL31432862 | 0.82 | ALDH1A1 (0.56) | ALDH1A1CACNA1HKDM4EUSP2GAA | |
| SCHEMBL602779 | 0.82 | EPHX2 (0.62) | ALDH1A1KDM4EEPHX2GAAKMT2A | |
| SCHEMBL19338412 | 0.80 | ALDH1A1 (0.53) | ALDH1A1CACNA1HKDM4EEPHX2GAA | |
| SCHEMBL5747672 | 0.80 | ERCC1 (0.45) | ALDH1A1KDM4EGAACYP1A2AOC2 | |
| SCHEMBL17730692 | 0.78 | HTT (0.50) | ALDH1A1CACNA1HKDM4EEPHX2GAA | |
| SCHEMBL13568602 | 0.78 | ALDH1A1 (0.55) | ALDH1A1KDM4EUSP2KMT2ACYP1A2 | |
| SCHEMBL20349602 | 0.78 | ALDH1A1 (0.48) | ALDH1A1KDM4EUSP2GAAKMT2A | |
| SCHEMBL6783952 | 0.76 | KDM4E (0.61) | ALDH1A1KDM4EUSP2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | ALDH1A1 143/4885CACNA1H 2602/4885KDM4E 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.